The new
drug, empaliflozin, reduces the risk for future cardiac events, including
premature death by 14% when added to conventional care.
This was in the front-page article of Family
Practice News in October.
However, the
TACT study of chelation produced a reduction of the same end points by about
50%.
Chelation also reduces the toxic
metal load for patients, which might lessen the risk of cancer and other
diseases.
If you are a diabetic, or even
a pre-diabetic, I urge you to consider chelation.
Without chelation, having diabetes shortens
the lifespan by 5-7 years.
Nothing works
better.
See Family Practice News, October 15, 2015, p. 1.
No comments:
Post a Comment